What Orbicular Pharmaceutical Technologies does

Orbicular Pharmaceutical Technologies (Pvt. Ltd.) is a Hyderabad, India-based specialty pharmaceutical product development company founded in 2010 that develops complex generic and specialty pharmaceutical dosage forms and out-licenses them to global pharmaceutical partners for commercialization. The company employs 251-500 staff including 200+ specialized scientists and operates under a Quality-by-Design framework with QMS ISO 9001:2008 certification.

Its core technology platform spans five complex dosage-form pillars defined by its CI-TOP SPIN strategy: Complex Injectables (microspheres, nano suspensions and emulsions, liposomes, high-end peptides, depot suspension injections, device-based peptide injections), Topicals (ointments, creams, gels, solutions, foams), Ophthalmics (gels, micro-emulsions, suspensions, preservative-free systems), Parenterals and Niche Injectibles (prefilled syringes, lyophilized injectables, high-potency compounds including hormones, cytotoxics, peptides, prostaglandins), and Sprays and Inhalations (nasal sprays, inhalation solutions). Leadership team members collectively hold 47+ granted U.S. patents and 20+ PCT applications, with prior experience at Strides, Dr. Reddy's, Mylan, Zydus Cadila, and Wockhardt.

The company operates a partnership-led, asset-light business model with two revenue streams: (i) late-stage out-licensing of developed products to global pharmaceutical partners in exchange for upfront payments, milestone payments, and royalties, and (ii) development service contracts for projects matching its capabilities. Notable commercialized assets include generic semaglutide injection (g-Ozempic) licensed to Apotex with US FDA Tentative Approval and Health Canada Notice of Compliance in 2026, generic liraglutide injection (g-Saxenda) launched in the US via Cipla in February 2026, and a dermatology joint venture with Alembic. The company operates a multi-party ecosystem with Shaily Engineering Plastics (pen-device platform), OneSource Specialty Pharma (CDMO manufacturing), and Gland Pharma (co-development). It received $20M from Tata Capital Healthcare Fund II in May 2024.

Name

Orbicular Pharmaceutical Technologies

Legal name

Orbicular Pharmaceutical Technologies Pvt. Ltd.

Website

https://orbicular.co.in

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

251–500 employees

Short description

Orbicular Pharmaceutical Technologies is a Hyderabad-based specialty pharmaceutical R&D company that develops complex generics across injectables, topicals, ophthalmics, parenterals, and inhalation dosage forms, out-licensing late-stage products to global pharma partners like Apotex and Cipla for commercialization.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceutical Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Specialty pharmaceutical development
• Complex generic formulations
• Injectable drug development
• Pharmaceutical out-licensing
• Contract pharmaceutical research

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Product Licensing: Developing niche generic and specialty pharmaceutical products and licensing them at late stages to global partners who commercialize the products in their respective markets. Revenue generated through upfront payments, milestone payments, and royalties on commercialized products.
2. Product Development Services: Providing outsourcing partnership services for pharmaceutical companies for projects that fit Orbicular's service capabilities. Revenue generated through development fees and service contracts.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Orbicular Pharmaceutical Technologies is a specialty pharmaceutical R&D company that develops niche and complex generic pharmaceutical dosage forms — including complex injectables, topicals, ophthalmics, parenterals, nasal sprays, and inhalations — and licenses the late-stage developed products to global pharmaceutical partners who handle commercialization across regulated and emerging markets. The company operates a partnership-driven model combining formulation development, IP/regulatory strategy, technology transfer, and co-development services for global drug manufacturers.

Product overview

Orbicular Pharmaceutical Technologies is a specialty pharmaceutical R&D company that develops complex generic and specialty pharmaceutical products across five core dosage form categories: Complex Injectables (microspheres, nano-formulations, liposomes, high-end peptides, depot injections, device-based peptide injections), Topicals (ointments, creams, gels, foams), Ophthalmics (gels, micro-emulsions, suspensions), Parenterals & Niche Injectibles (prefilled syringes, lyophilized injectables, high-potency compounds), and Sprays & Inhalations (nasal sprays, inhalation solutions). The company operates a partnership-driven business model, licensing late-stage developed products to global pharmaceutical partners. Notable products include generic semaglutide injection (g-Ozempic) with USFDA and Health Canada approvals, and generic liraglutide injection (generic Saxenda) approved for the US market.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Successfully obtained US FDA Tentative Approval and Health Canada Notice of Compliance for generic semaglutide injection - first such approvals for generic Ozempic in Canada
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core, flagship, supporting and major.

• Shaily Engineering PlasticscoreStrategic or Co-development Partner · 21 May 2026Strategic partnership using Shaily's proprietary ShailyPen Neo spring-driven pen injector platform for generic semaglutide injection. The combination product received USFDA Tentative Approval, Health Canada Notice of Compliance, and India CDSCO approval. ShailyPen Neo is among a rare class of commercially available spring-driven pen injectors globally, offering full compatibility with ISO-standard 3 mL cartridges.
• Apotex Inc.flagshipStrategic or Co-development Partner · 5 May 2026Strategic partnership with Apotex for development and commercialization of generic semaglutide injection (generic Ozempic). The product received Health Canada Notice of Compliance and US FDA Tentative Approval. Apotex commercializes the product in Canada as Apo-Semaglutide Injection in 2mg and 4mg prefilled pen formats. This represents back-to-back G7 regulatory authorizations for an entirely India-developed product.
• Gland PharmasupportingStrategic or Co-development Partner · 27 April 2026Collaborative partnership involving combined scientific, regulatory, and manufacturing capabilities for generic Infuvite Pediatric and Adult Injection products. Apotex served as the ANDA sponsor leading US commercialization while Orbicular and Gland Pharma contributed to development and manufacturing.
• OneSource Specialty PharmacoreTechnology or Integration · 21 April 2026CDMO partnership where OneSource provides end-to-end manufacturing capabilities from its US-FDA approved facility in Bangalore, India. Orbicular leads product development and technical program for complex peptide products including generic semaglutide injection. The collaboration ensures reliable commercial supply to the US market pending final approval.
• Cipla USA Inc.majorStrategic or Co-development Partner · 27 February 2026Partnership for generic Liraglutide Injection (generic Saxenda) launch in the US market for weight management therapy. The launch targets the US GLP-1 weight management market valued at approximately $127 million, strengthening Cipla's US portfolio as one of the few companies offering generic versions of both Victoza and Saxenda.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Cipla: Major Indian generic and specialty pharmaceutical company with global reach including US generics and respiratory/inhalation franchises. Direct peer and Orbicular's commercialization partner for generic liraglutide in the US.
• Glenmark Pharmaceuticals: Indian specialty pharma company with strong complex generics, dermatology, and respiratory franchises. Direct peer with overlapping specialty dosage-form capabilities and global partnership model.
• Lannett Company: US-based specialty generics developer focused on complex dosage forms including injectables, topicals, and ophthalmics. Direct peer with comparable business model of developing niche, complex generics for licensing or distribution.
• Apotex: Canadian-headquartered generic pharmaceutical company with significant complex generics and specialty portfolio. Direct peer and Orbicular's lead commercialization partner for generic semaglutide in Canada and the US.
• Piramal Pharma Solutions: Indian-headquartered pharma services and CDMO with strong complex injectable and specialty formulation capabilities. Direct peer in the Indian complex-generics development and manufacturing services space.
• Alembic Pharmaceuticals: Indian specialty and generic pharmaceutical company. Direct peer and JV partner — Orbicular and Alembic operate a dermatology joint venture, and both target complex generics and specialty pharma in the Indian and global markets.

Broad incumbents

• Endo International: US specialty pharmaceutical company historically focused on sterile injectables, generics, and complex dosage forms. Broader incumbent with comparable specialty injectable portfolio and licensing/partnership model.
• Dr. Reddy's Laboratories: Large Indian pharmaceutical company with broad generic and specialty pharma operations including injectables and complex formulations. Broader incumbent — Orbicular's founders came from Dr. Reddy's leadership, and DRL competes across many of the same dosage forms and geographies.
• Aurobindo Pharma: One of India's largest generic pharma companies with significant injectable and complex generics exposure in regulated markets. Broader incumbent competing with Orbicular's partners and itself developing complex generics.

Emerging players

• Biocon: Indian biopharmaceutical company specializing in biosimilars, generic peptides, and complex injectables. Emerging peer with comparable peptide injectable focus, including programs in GLP-1 analogues.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orbicular Pharmaceutical Technologies